KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Goodwill & Intangibles: 2022-2024

Historic Goodwill & Intangibles for Halozyme Therapeutics (HALO) over the last 3 years, with Dec 2024 value amounting to $818.7 million.

  • Halozyme Therapeutics' Goodwill & Intangibles fell 8.49% to $765.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $765.4 million, marking a year-over-year decrease of 8.49%. This contributed to the annual value of $818.7 million for FY2024, which is 7.99% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Goodwill & Intangibles of $818.7 million as of FY2024, which was down 7.99% from $889.7 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Goodwill & Intangibles ranged from a high of $955.7 million in FY2022 and a low of $818.7 million during FY2024.
  • Over the past 3 years, Halozyme Therapeutics' median Goodwill & Intangibles value was $889.7 million (recorded in 2023), while the average stood at $888.0 million.
  • Data for Halozyme Therapeutics' Goodwill & Intangibles shows a maximum YoY fell of 7.99% (in 2024) over the last 5 years.
  • Over the past 3 years, Halozyme Therapeutics' Goodwill & Intangibles (Yearly) stood at $955.7 million in 2022, then fell by 6.91% to $889.7 million in 2023, then fell by 7.99% to $818.7 million in 2024.